[Federal Register Volume 60, Number 179 (Friday, September 15, 1995)]
[Notices]
[Pages 47956-47957]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-22992]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. ]
Prospective Grant of Exclusive License: Veterinary Vaccine and
Therapeutic Uses of Bartonella Henselae (Formerly Rochalimaea Henselae)
Organisms
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a worldwide, limited field of use, exclusive license to practice the
inventions embodied in the patents and patent applications referred to
below to Paravax, Inc., having a place of business in Fort Collins,
Colorado. The patent rights in these inventions have been assigned to
the government of the United States of America. The patents and patent
applications to be licensed are: ``Methods and Compositions for
Diagnosing Cat Scratch Disease and Bacillary Angiomatosis Caused by
Rochalimaea henselae,'' U.S. Patent Application Serial No. 07/822,539
filed 17 Jan 92 (U.S. Patent No. 5,399,485 issued 21 Mar 95) and
related cases, which include all continuation applications, divisional
applications, continuation-in-part applications, and foreign
counterpart applications.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within sixty
(60) days from the date of this published notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the
[[Page 47957]]
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Bartonella henselae (formerly Rochalimaea henselae) causes no
currently known clinical disease in cats, but it has been identified as
the cause of Cat Scratch Disease (CDS) in humans. Cats infected with
Bartonella henselae have been identified as the source or reservoir of
these infections in humans where a mild to severe lymphadenopathy can
result. Further manifestations of Bartonella henselae may include
Parinaud oculoglandular syndrome, prolonged fever associated with
relapsing bacteremia, bacillary angiomatosis, and endocarditis and
bacillary peliosis. The sick and elderly, especially immunocompromised
susceptible to infection.
Centers for Disease Control and Prevention (CDC) scientists have
discovered a method of diagnosing cat scratch disease and a method of
diagnosing bacillary angiomatosis in a subject by detecting the
presence of Bartonella henselae or an immunogenically specific
determinant thereof in the subject, as well as vaccines comprising
Bartonella henselae or fragments thereof.
ADDRESSES: Requests for a copy of these patent applications, inquiries,
comments, and other materials relating to the contemplated license
should be directed to: Carol C. Lavrich, Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852.
Telephone: (301) 496-7735, ext. 287; Facsimile: (301) 402-9220.
Applications for a license filed in response to this notice will be
treated as objections to the grant of the contemplated license. Only
written comments and/or applications for a license which are received
by NIH on or before November 14, 1995, will be considered. Comments and
objections submitted in response to this notice will not be made
available for public inspection, and, to the extent permitted by law,
will not be released under the Freedom of Information Act, 5 U.S.C.
552. A signed Confidential Disclosure Agreement will be required to
receive a copy of any pending application.
Dated: August 23, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-22992 Filed 9-14-95; 8:45 am]
BILLING CODE 4140-01-P
